Fast Five Quiz: Urothelial Carcinoma

Kyle A. Richards, MD


August 13, 2020

The NCCN treatment guidelines recommend the combination of dose-dense DDMVAC with growth factor support as perioperative chemotherapy for muscle invasive bladder cancer.

The guidelines recommend perioperative gemcitabine and cisplatin as a reasonable alternative to DDMVAC; a 21-day cycle is preferred.

MVAC is not recommended because it is associated with dose-limiting myelosuppression. DDMVAC is preferred because it is better tolerated and more effective in patients with advanced disease.

For patients who are not candidates for cisplatin, there are no data to support a recommendation for perioperative chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Carboplatin should not be substituted for cisplatin in the perioperative setting.

Learn more about medication options for urothelial carcinoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: